Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2005

Mussak EN, Tu JJ, Voigt EP. Malignant solitary fibrous tumor of the hypopharynx with dysphagia. Otolaryngol Head Neck Surg. 2005;133(5):805-7.

Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, et al. p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A. 2005;102(32):11355-60.

Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med. 2005;353(22):2342-51.

Simmons WJ, Koneru M, Mohindru M, Thomas R, Cutro S, Singh P, et al. Tim-3+ T-bet+ tumor-specific Th1 cells colocalize with and inhibit development and growth of murine neoplasms. J Immunol. 2005;174(3):1405-15.

Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu M-, et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005;11(24 Pt 1):8623-31.

Siddiqui MT, Gokaslan ST, M Saboorian H, Ashfaq R. Split sample comparison of ThinPrep and conventional smears in endoscopic retrograde cholangiopancreatography-guided pancreatic fine-needle aspirations. Diagn Cytopathol. 2005;32(2):70-5.

Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, et al. The transcriptional landscape of the mammalian genome. Science. 2005;309(5740):1559-63.

Aslan DL, H Gulbahce E, Pambuccian SE, J Manivel C, Jessurun J. Ki-67 immunoreactivity in the differential diagnosis of pulmonary neuroendocrine neoplasms in specimens with extensive crush artifact. Am J Clin Pathol. 2005;123(6):874-8.

Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538-43.

Lesinski GB, Valentino D, Hade EM, Jones S, Magro C, Chaudhury AR, et al. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. Cancer Immunol Immunother. 2005;54(9):815-25.